Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.38 |
| ▸ | PPARA | Q07869 | 6/20 | 0.38 |
| ▸ | PPARD | Q03181 | 3/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.37 |
| ▸ | PPARG | P37231 | 3/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7424591 | 0.82 | GAA (0.49) | F2PPARAPPARDPARP10CACNA1B | |
| SCHEMBL5866124 | 0.77 | CHRNB2 (0.44) | PPARDMAPTL3MBTL1 | |
| SCHEMBL5866235 | 0.77 | CACNA1B (0.53) | F2CACNA1B | |
| Hydrochloric Acid SCHEMBL5866267 | 0.76 | CACNA1B (0.52) | F2CACNA1B | |
| SCHEMBL5866233 | 0.70 | F2 (0.41) | F2PPARAPPARDPPARG | |
| SCHEMBL5866239 | 0.70 | F2 (0.41) | F2PPARAPPARDPPARG | |
| SCHEMBL5866156 | 0.69 | F2 (0.34) | F2TDP1ALDH1A1MAPT | |
| SCHEMBL5866148 | 0.69 | F2 (0.34) | F2TDP1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL5866265 | 0.69 | F2 (0.40) | F2PPARAPPARDPPARG | |
| SCHEMBL5866133 | 0.68 | PPARD (0.48) | F2PPARAPPARDPPARGALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074820-B2 | Amidino derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2006-07-11 | — | — | US | disclosed |
| EP-0917528-B1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-18 | — | — | EP | disclosed |
| US-20020040043-A1 | Amidino derivatives and their use as thrombin inhibitors | ANTONSSON THOMAS (SE) | 2002-04-04 | — | — | US | disclosed |
| US-6221898-B1 | ANTICOAGULANTS | ASTRA AKTIEBOLAG (SE) | 2001-04-24 | — | — | US | disclosed |
| EP-0917528-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | Astra Aktiebolag (SE) | 1999-05-26 | — | — | EP | disclosed |
| WO-1998001422-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRA AKTIEBOLAG (SE) | 1998-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040043-A1 | Amidino derivatives and their use as thrombin inhibitors | SERPINC1, F2, SERPINE1 | F2 2/4885PPARA 3313/4885PPARD 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.